Annexin A2 plays a critical role in epithelial ovarian cancer

Deng, Yan; Chen, Chen; Mao, Hua; Xi, Qinghua; Liu, Rong; Yang, Shuyun; Liu, Jian; Zhong, Jun; Tang, Meilan; Lu, Sen; Tang, Chunhui; Wang, Yingying

doi:10.1007/s00404-014-3598-5

Cited by 22 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present data, AnxA2 showed high abundance on 2‐DE map of OC relative to control tissue samples. In that, AnxA2 has previously been found associated with OC in the literature, where some researchers reported its upregulation while others described its downregulation, relative expression of AnxA2 further validated by WB. In concordance with 2‐DE data, WB analysis confirmed upregulation of AnxA2 in OC comparative to the control tissues (Figure 3A,B).…”

Section: Resultsmentioning

confidence: 84%

See 1 more Smart Citation

Upregulated Expression of Calcium‐Dependent Annexin A6: A Potential Biomarker of Ovarian Carcinoma

Noreen

Gardner

Fatima

et al. 2020

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose An early and accurate diagnosis of ovarian carcinoma (OC) may reduce morbidity and mortality of the patients. To improve the clinical outcome in OC patients, the present study is aimed at identifying robust biomarkers for early OC diagnosis. Experimental Design In order to look for early‐stage protein markers, a systematic protein profiling approach involving 2‐dimensional electrophoresis coupled with mass spectrometric analyses of human malignant and non‐malignant ovarian biopsy samples, is performed. Results Six 2D gel spots, corresponding to five proteins, display statistically significant differential expression in the tumor tissues compared to benign controls (FDR ≤ 0.05; PMF score ≥ 79). Ingenuity pathway analysis predicts two proteins, that is, Ca2+‐dependent membrane‐binding protein annexin A6 (AnxA6) and the metabolic enzyme l‐lactate dehydrogenase A chain, as potential predictive biomarkers. Increased expression of AnxA6 is further ascertained by Western blot and enzyme linked immunosorbent assay in the resected tissues and the plasma samples. The expression is found markedly increasing particularly in the advanced stage tumors. Conclusions and Clinical Relevance The significant upregulation of AnxA6 in OC, reported for the first time, is likely to provide insight into the mechanism of OC progression, which may lead to the design of potential diagnostic and therapeutic strategies.

show abstract

Section: Resultsmentioning

confidence: 84%

“…However, AnxA2 regulation in OC was found disputed, some researchers reporting its high abundance while another study reported low abundance in OC. Our study showed upregulation of AnxA2 in 80% OC cases by WB.…”

Section: Discussionmentioning

confidence: 99%

Upregulated Expression of Calcium‐Dependent Annexin A6: A Potential Biomarker of Ovarian Carcinoma

Noreen

Gardner

Fatima

et al. 2020

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…Loss of heterozygosity (LOH) and gene sequencing analysis investigate the possibility of CNTN4 to function as tumor suppressor gene in ovarian cancer [56]. ANXA2 is a calcium-binding cytoskeletal protein aberrantly expressed in a wide spectrum of cancers and in EOC may promote cell proliferation [57]. …”

Section: Resultsmentioning

confidence: 99%

Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma

et al. 2016

View full text Add to dashboard Cite

Understanding the biology and molecular pathogenesis of ovarian epithelial cancer (EOC) is key to developing improved diagnostic and prognostic indicators and effective therapies. Although research has traditionally focused on the hypothesis that high-grade serous carcinoma (HGSC) arises from the ovarian surface epithelium (OSE), recent studies suggest that additional sites of origin exist and a substantial proportion of cases may arise from precursor lesions located in the Fallopian tubal epithelium (FTE). In FTE cells, the transcription factor PAX8 is a marker of the secretory cell lineage and its expression is retained in 96% of EOC. We have recently reported that PAX8 is involved in the tumorigenic phenotype of ovarian cancer cells. In this study, to uncover genes and pathways downstream of PAX8 involved in ovarian carcinoma we have determined the molecular profiles of ovarian cancer cells and in parallel of Fallopian tube epithelial cells by means of a silencing approach followed by an RNA-seq analysis. Interestingly, we highlighted the involvement of pathways like WNT signaling, epithelial-mesenchymal transition, p53 and apoptosis. We believe that our analysis has led to the identification of candidate genes and pathways regulated by PAX8 that could be additional targets for the therapy of ovarian carcinoma.

show abstract

“…70E-02 tissue [55] Q9JJ19 Na (+)/H (+) exchange regulatory cofactor (NHRF1) [56] P24594 Insulin-like growth factor-binding protein 5 (IBP5)…”

Section: Urine Proteome Changes In Nutu-19 Cell Intraperitoneal-injecmentioning

confidence: 99%

“…is overexpressed in carcinoma tissues compared with normal tissue and has a critical role in EOC cell proliferation; it has the potential to be used as a novel therapeutic target for EOC [56] . Insulin-like growth factor-binding protein 5 (IBP5) is overexpressed in high-grade serous carcinomas compared to normal surface epithelium and might play a role in the development of this disease [66] .…”

Section: Urine Proteome Changes In Nutu-19 Cell Intraperitoneal-injecmentioning

confidence: 99%

Dynamic changes in the urine proteome in two ovarian cancer rat models

Zhang

Meng

et al. 2019

Preprint

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological malignancy in women, and it is likely to metastasize and has a poor prognosis. The early and reliable diagnosis and monitoring of ovarian cancer is very important. Without a homeostasis mechanism, urine can reflect early systemic changes in the body and has a great potential to be used for the early detection of cancer. This study tested whether early changes could be detected in two ovarian cancer rat models. Two rat models were established by either intraperitoneal (i.p.) or orthotopic (o.t.) injection of NuTu-19 ovarian cancer cells in female Fischer344 rats. Urine samples from ovarian cancer rats were collected at five time points during cancer development, and urinary proteins from the rats were profiled by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Compared with pre-injection samples, 49 differential proteins that have human orthologues were significantly changed in the orthotopically injected model. Among them, 24 of the differential proteins have previously been reported to be associated with ovarian cancer, six of which were reported to be biomarkers of ovarian cancer. On the 7th day after orthotopic injection, four differential proteins (APOA1, OX2G, CHMP5, HEXB) were identified before obvious metastases appeared. In the intraperitoneal injection model, 76 differential proteins were changed during the course of ovarian cancer development. The results show that urine proteins could enable the early detection and monitoring of ovarian cancer progression and could lay a foundation for further exploration of the biomarkers of ovarian cancer. IntroductionOvarian cancer (OC) is the most lethal gynecological malignancy and it is the fifth leading cause of cancer death in women [1] , mainly because OC can spread to intraperitoneal tissues, such as the omentum in the peritoneal cavity, by the time of diagnosis [2] . The strongest risk factors for this disease are an advanced age and a family history of ovarian cancer. Epithelial ovarian cancer (EOC) is the most common ovarian malignancy and comprises 90% of all ovarian cancers [3] . More than 75% of affected women ovarian carcinomas are not diagnosed until a late stage (stage III or IV) because early-stage disease is not obvious and early symptoms, as well as symptoms of late-stage disease, are nonspecific.Pelvic or abdominal pain, a feeling of pelvic mass and abdominal swelling are the main clinical symptoms, but these are not specific to OC [4] . Currently, women who have symptoms consistent with ovarian cancer usually undergo a physical examination, transvaginal ultrasonography, and measurement of biomarkers such as CA125, but imaging and serum biomarkers tests are of limited 2 value in the early diagnosis of the ovarian carcinomas [5] . The treatment of ovarian cancer usually involves surgery and intraperitoneal and intravenous chemotherapy [6] . At present, patients are typically diagnosed at the advanced stage when the cancer has disseminated within the peritoneal cavity, and comp...

show abstract

Annexin A2 plays a critical role in epithelial ovarian cancer

Abstract: We could hypothesize that Annexin A2 acted a critical role in EOC cell proliferation, and may be used as a potential and novel therapeutic target for EOC. These data suggest that Annexin A2 may promote the progression of EOC and be a therapeutic target for EOC therapy.

Cited by 22 publications

References 24 publications

Upregulated Expression of Calcium‐Dependent Annexin A6: A Potential Biomarker of Ovarian Carcinoma

Upregulated Expression of Calcium‐Dependent Annexin A6: A Potential Biomarker of Ovarian Carcinoma

Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma

Dynamic changes in the urine proteome in two ovarian cancer rat models

Contact Info

Product

Resources

About